普洛药业：获得左卡尼汀注射液药品注册证书

Core Viewpoint - Prolo Pharmaceutical (000739) announced that its subsidiary, Zhejiang Prolo Kangyu Pharmaceutical Co., Ltd., received a drug registration certificate for L-carnitine injection from the National Medical Products Administration, indicating a significant development in its product portfolio [1] Company Summary - Prolo Pharmaceutical's subsidiary has obtained regulatory approval for L-carnitine injection, which is clinically used for complications arising from secondary carnitine deficiency in patients with chronic renal failure undergoing long-term hemodialysis [1] - The approval is expected to enhance the company's market presence in the pharmaceutical sector, particularly in the treatment of chronic kidney disease [1] Industry Summary - The market size for L-carnitine injection in China's hospital sector is projected to reach 103 million units with a sales value of 965 million yuan in 2024, indicating a substantial opportunity for growth in this therapeutic area [1]